Oncurious Announces Publication in Journal for Immunotherapy of Cancer highlighting the efficacy and safety of targeting CCR8 for the depletion of tumor-promoting Tumor Infiltrating Tregs in combination with anti-PD-1 therapy

24 Feb 2021

Leuven, Belgium - 24 February 2021 – ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments designed to enhance T cell migration, infiltration and activity into resistant tumour sites, today reports the publication of a paper in the Journal for Immunotherapy of Cancer (a BMJ journal) entitled “Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy”.

This publication provides further validation for CCR8, a chemokine receptor tumor-infiltrating Treg-specific marker in solid tumors, as a preferred target for therapeutic depletion of Tregs in cancer. A link to the online open access article can be found here:

Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy | Journal for ImmunoTherapy of Cancer (bmj.com)

Downregulation of T cells is an immunosuppressive mechanism commonly used by tumors to evade the body’s immune response and as such is an attractive target for new therapeutic modalities. By targeting CCR8, Oncurious hopes to overcome tumor resistance mechanisms that current immune checkpoint inhibitors cannot address, and thereby significantly enhance the breadth and depth of responses to therapy.

Oncurious, in collaboration with world-class immuno-oncology experts in T cell and endothelial cell biology and the drug discovery unit at VIB, is building a pipeline of proprietary investigational I-O therapies with distinct modes of action. The team has discovered a potent and diverse panel of leads targeting human CCR8 and is entering the final lead optimization stages nearing preclinical candidate selection.